ImmunityBio Shares Tumble as Legal Challenges Mount

ImmunityBio is facing mounting pressure from multiple directions, including regulatory warnings and a surge of investor lawsuits. The biopharmaceutical company saw its stock decline by nearly 10% on Monday, closing at $6.66, as the market reacted to these compounded challenges.

Legal Actions Trigger Market Decline

The recent sell-off was precipitated by a series of securities class action complaints filed on March 30, 2026. Prominent U.S. law firms, including Hagens Berman and Bragar Eagel & Squire, are leading the litigation. The suits center on public statements made by Executive Chairman Dr. Patrick Soon-Shiong during a podcast and a television advertisement.

These promotional claims for the drug ANKTIVA were flagged by the U.S. Food and Drug Administration (FDA) as misleading. The agency identified that the communications implied ANKTIVA could treat "all cancers," a claim not supported by its regulatory approvals. Since the initial disclosure of the FDA's warning letter, ImmunityBio has lost approximately $2 billion in market capitalization.

Should investors sell immediately? Or is it worth buying ImmunityBio?

Investors who purchased the company's equity between January 19 and March 24, 2026, have until May 26, 2026, to file as lead plaintiffs in the ongoing litigation.

Regulatory and Commercial Crosscurrents

While navigating these legal and regulatory headwinds, the company has received significant clinical validation. The National Comprehensive Cancer Network (NCCN) updated its 2026 clinical guidelines to include ANKTIVA in combination with BCG for certain forms of non-muscle invasive bladder cancer. This endorsement strengthens the product's commercial foundation and represents a key operational bright spot.

However, the FDA has mandated that ImmunityBio respond to the cited promotional violations within 15 days and outline corrective actions. A critical question for the company's near-term trajectory is whether it can resolve this regulatory dispute without jeopardizing its planned supplemental Biologics License Application (BLA) submissions slated for later in 2026.

Despite the recent decline, the share price remains well above its 200-day moving average of $4.25. This level is seen as reflecting the clinical progress the company achieved throughout the preceding year, even as current challenges dominate investor sentiment.

Ad

ImmunityBio Stock: New Analysis - 31 March

Fresh ImmunityBio information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated ImmunityBio analysis...

US45256X1037 | IMMUNITYBIO | boerse | 69033728 |